After Fine, Botox Awaits Approval for Migraine
Wednesday, September 8, 2010 - 23:07
in Mathematics & Economics
Allergan agreed to pay $600 million for Botox’s marketing getting ahead of approved uses. But the F.D.A. will soon decide on its effectiveness for migraines.